NCT03202134

Brief Summary

The Deep Inferior Epigastric Perforator free flap (DIEPflap) involves the transfer of abdominal tissue to the breast using microsurgery. Flap failure is rare today, but is devastating. Blood flow in a DIEPflap decreases during the first hours. Many anesthetic factors like low cardiac output, hypothermia and surgical stress cause vasoconstriction or thrombosis. A stable anesthesia during these long procedures improves flap perfusion. Postoperative nausea and vomiting (PONV) is frequent and might have an impact. Opioid free anesthesia (OFA) reduces PONV. The anti-inflammatory and vasodilator effects of the drugs dexmedetomidine and lidocaine might improve free flap perfusion. The primary outcome counted all complications. The secondary outcomes were PONV, pain, opioid consumption, skin flap temperature and length of hospital stay. Patients get according to attending anesthesiologist an opioid or opioid free anesthesia without any randomization but based on availability of competence.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
204

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2014

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2014

Completed
3.5 years until next milestone

First Submitted

Initial submission to the registry

June 26, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 28, 2017

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 15, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 15, 2019

Completed
1.3 years until next milestone

Results Posted

Study results publicly available

February 23, 2021

Completed
Last Updated

February 23, 2021

Status Verified

February 1, 2021

Enrollment Period

5.9 years

First QC Date

June 26, 2017

Results QC Date

December 10, 2019

Last Update Submit

February 4, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of Patients With One or More Complications

    number of minor and major complications (CLAVIEN) (DINDOO)

    One month postoperative

Secondary Outcomes (5)

  • Number of Patients With Post Operative Nausea or Vomiting

    24 hours postoperative

  • Postoperative Pain: Visual Analog Scale

    24 hours postoperative

  • Morphine Used

    24 hours postoperative

  • Skin Temperature

    24 hours post operative

  • Length of Hospital Stay

    up to two weeks

Study Arms (2)

opioid free anesthesia (OFA)

The method of reaching OFA: Dexmedetomidine was given in a first loading dose 15 minutes before induction, a second loading dose at induction followed by an infusion for maintenance. Lidocaine is given as a loading dose at induction followed by infusion for maintenance. A Ketamine loading dose is given at induction with an extra bolus before incision followed by an infusion.

Other: opioid free anesthesia

opioid anesthesia (OA)

OA was induced with sufentanil and continued with extra boli or a continuous infusion of remifentanil.

Interventions

general anesthesia blocking reflexes without using an opioid

opioid free anesthesia (OFA)

Eligibility Criteria

Age18 Years - 75 Years
Sexfemale(Gender-based eligibility)
Gender Eligibility Detailsbreast reconstructive surgery is included
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

woman who are admitted for breast reconstruction using the diepflap (free flap)

You may not qualify if:

  • allergy to any of the drugs used in anesthesia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Azsintjan

Bruges, 8000, Belgium

Location

Results Point of Contact

Title
Jan Mulier
Organization
AZSintJanAV

Study Officials

  • Jan Paul Mulier

    AZSint Jan AV

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
1 Month
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
chairman dep anesthesiology & Reanimation

Study Record Dates

First Submitted

June 26, 2017

First Posted

June 28, 2017

Study Start

January 1, 2014

Primary Completion

November 15, 2019

Study Completion

November 15, 2019

Last Updated

February 23, 2021

Results First Posted

February 23, 2021

Record last verified: 2021-02

Data Sharing

IPD Sharing
Will not share

Locations